Abstract:Abstract Aberrant activation of the PI3K/AKT signaling axis along with the sustained phosphorylation of downstream BAD is associated with a poor outcome of TNBC. Herein, the phosphorylated to non-phosphorylated ratio of BAD, an effector of PI3K/AKT promoting cell survival, was observed to be correlated with worse clinicopathologic indicators of outcome, including higher grade, higher proliferative index and lymph node metastasis. The structural optimization of a previously reported inhibitor of BAD-Ser99 phosphorylation was therefore achieved to generate a small molecule inhibiting the phosphorylation of BAD at Ser99 with enhanced potency and improved oral bioavailability. The molecule 2-((4-(2,3-dichlorophenyl)piperazin-1-yl)(pyridin-3-yl)methyl) phenol (NCK) displayed no toxicity at supra-therapeutic doses and was therefore assessed for utility in TNBC. NCK promoted apoptosis and G0/G1 cell cycle arrest of TNBC cell lines in vitro, concordant with gene expression analyses, and reduced in vivo xenograft growth and metastatic burden, demonstrating efficacy as a single agent. Additionally, combinatorial oncology compound library screening demonstrated that NCK synergized with tyrosine kinase inhibitors (TKIs), specifically OSI-930 or Crizotinib in reducing cell viability and promoting apoptosis of TNBC cells. The synergistic effects of NCK and TKIs were also observed in vivo with complete regression of a percentage of TNBC cell line derived xenografts and prevention of metastatic spread. In patient-derived TNBC xenograft models, NCK prolonged survival times of host animals, and in combination with TKIs generated superior survival outcomes to single agent treatment. Hence, this study provides proof of concept to further develop rational and mechanistic based therapeutic strategies to ameliorate the outcome of TNBC.

Inhibition of the CDK9–cyclin T1 protein–protein interaction as a new approach against triple-negative breast cancer

Discovery of a Tetrahydroisoquinoline-Based CDK9-cyclin T1 Protein–protein Interaction Inhibitor As an Anti-Proliferative and Anti-Migration Agent Against Triple-Negative Breast Cancer Cells

Design, Synthesis, and Biological Evaluation of Novel 4,4′-Bipyridine Derivatives Acting As CDK9-Cyclin T1 Protein-Protein Interaction Inhibitors Against Triple-Negative Breast Cancer

Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer

Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer

Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer

Discovery of Novel PI3K/CDK2 Dual Inhibitor Based on 7-Azaindole Derivatives As a Promising Strategy for Triple-Negative Breast Cancer Therapy

Design, Synthesis and Anticancer Evaluation of Selective 2,4-Disubstituted Pyrimidine CDK9 Inhibitors

Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism

N76-1, a novel CDK7 inhibitor, exhibits potent anti-cancer effects in triple negative breast cancer

Elucidating Binding Selectivity in Cyclin-Dependent Kinases (CDKs) 4, 6, and 9: Development of Highly Potent and Selective CDK4/9 Inhibitors

Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.

Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer

Structure-guided design and cloning of peptide inhibitors targeting CDK9/cyclin T1 protein-protein interaction

Design, Synthesis and Structure-Activity Relationship Studies of a Focused Library of Pyrimidine Moiety with Anti-Proliferative and Anti-Metastasis Activities in Triple Negative Breast Cancer.

Structure-Based Design of 2-Aminopurine Derivatives As CDK2 Inhibitors for Triple-Negative Breast Cancer

Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer

Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple‐Negative Breast Cancer

Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer

Discovery and optimization of thieno[3,2- d ]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7

Discovery of Selective CDK9 Degraders with Enhancing Antiproliferative Activity Through PROTAC Conversion